Autologous Stem Cell Collection In Lymphoma and Myeloma Patients: Single Center Analysis With Intention To Successful Mobilization and Collection Under Restricted Permission For Use Of Plerixafor

High dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplantation (HSCT) rescue is a potentially curativec p<0.001, p=0.002 and p=0.001). Successful ASCT is achieved in 144 patients transplanted so far. Mobilization is achieved in almost all multiple myeloma patients and most of lymphoma patients with only G-CSF based regimen in our cohort. Half of patients not mobilized with G-CSF were successfully mobilized with chemotherapy and plerixafor as second or third line regimen. The restricted use of plerixafor resulted in time and expense for additional chemotherapy and collection attempt, whereas this inconvenience did not impact the success of stem mobilization and collection in our current policy within 3 years. Disclosures: No relevant conflicts of interest to declare.